Abstract: Herein provided is a new soybean variety designated ‘G13LL-44’ as well as the seeds, plants and derivatives of the new soybean variety ‘G13LL-44’. Also provided are tissue cultures of the new soybean variety ‘G13LL-44’ and the plants regenerated therefrom. Methods for producing soybean plants by crossing the new soybean variety ‘G13LL-44’ with itself or another soybean variety and plants produced by such methods are also provided. ‘G13LL-44’ is a MG VII line with glufosinate tolerance technology, and with resistance to race 3 of the soybean cyst nematode and frogeye leaf spot, and moderate resistance to southern root-knot nematode. ‘G13LL-44’ yielded 1.4 bu/ac (2.3%) greater than its recurrent parent ‘G00-3213’, across 11 environments and 0.5 bu/ac more than the high-yielding check cultivar ‘AG738 RR’. ‘G13LL-44’ provides a high yielding glufosinate tolerant soybean cultivar with superior nematode resistance.

Abstract: The present invention provides method of classifying a subject into a necrotizing meningoencephalitis (NME) disease risk group. The method may include assessing the presence of one or more marker (e.g., SNPs or risk loci) in a sample from the subject. For example, detection of the presence of one or more markers that are associated with an increased risk of NME can indicate that the subject should be classified into a risk group.

Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.

Abstract: The present disclosure provides engineered photosynthetic cells and organisms, methods for engineering photosynthetic cells and organisms with increased extracellular electron transport, photo-bioelectrochemical cells (PBECs), anodes for a PBECs and/or photosynthetic microbial fuel cells (PMFCs), methods of generating an electrical current with PBECs, and methods and systems for generating H2 fuel.

Abstract: Provided herein is a genetically engineered microbe which accumulates citramalate. In one embodiment, the microbe includes an exogenous polynucleotide encoding a citramalate synthase which catalyzes the condensation of acetyl CoA and pyruvic acid. Optionally, the microbe also includes a second exogenous polynucleotide encoding a citrate synthase which catalyzes the condensation of acetyl CoA and oxaloacetate, and the citrate synthase activity in the microbe is reduced compared to a control microbe. In one embodiment, the citrate synthase includes at least one amino acid substitution in the acetyl-CoA binding pocket, the mobile loop, the NADH binding site, and the oxaloacetate binding site, or a combination thereof. Also provided herein are methods for using the genetically engineered microbe, including a method for producing citramalate. The method can further include isolating the citramalate.

Abstract: The invention generally provides methods of treating or preventing infection and/or disease associated with different fungal pathogens in a subject in need, using an isolated antiserum generated against an immunogenic peptide of one fungal pathogen that contains antibodies that cross-protect the subject from infection and/or disease associated with one or more different fungal pathogens. The antiserum may be generated against a Kexin peptide derived from one of a Pneumocystis, Aspergillus, Candida, or Cryptococcus fungal pathogen. The resulting cross-protective, isolated antiserum may be used as a therapeutic for treating or protecting a subject who receives the antiserum against infection and/or disease associated with multiple fungal pathogens, in addition to the pathogen against which the antiserum is generated.

Abstract: The present invention relates to 2?-Fluoro-b?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

Abstract: Devices for non-invasive, label-free separation of particles in liquid, including circulating tumors cells in blood, are provided. Embodiments of the disclosure provide for devices employing magnetic fluids and magnets for separation of circulating tumor cells from blood. Methods for separation of particles including circulating tumor cells are also provided.

Abstract: Photodynamic therapy systems comprising a nanoparticle that emits electromagnetic radiation having a first wavelength when irradiated with electromagnetic radiation, a photosensitizer which absorbs electromagnetic radiation of said first wavelength and a biocompatible mesoporous material are disclosed herein. In some examples, the photodynamic therapy system comprises a core comprising the nanoparticle, a first shell comprising the biocompatible mesoporous material, and a photosensitizer embedded in the first shell. Upon irradiation by, for example, X-rays, the nanoparticle can function as a transducer, converting X-ray photons to visible photons, and in turn, activating the photosensitizers. Methods of using the photodynamic therapy system are also disclosed.

Abstract: Described herein are compounds that can bind CaSR and/or a CaSR extracellular domain and formulations thereof. Also described herein are methods of inhibiting CaSR and/or treating a disease or disorder associated with a mutation in CaSR by administering a compound or formulation thereof described herein. Also described herein are assays that can be used to identify compounds that can bind an extracellular domain of CaSR.

Abstract: Methods and compositions disclosed herein generally relate to genes involved in plant reproduction and methods of using the same.

Abstract: The present invention relates to methods of replicating viruses in vitro. In particular, the invention relates to a genetically modified population of cells, and/or a population of cells treated with an exogenous compound, wherein the cells are capable of producing more virus than cells lacking the genetic modification and/or lacking treatment with the exogenous compound. The invention also relates to methods of producing populations of such cells, as well as the use of the viruses obtained to prepare vaccine compositions.

Abstract: A new crapemyrtle plant has deep, uniform purple foliage and stems; a light lavender to white flower color; an intermediate upright growth habit; and powdery mildew and Cercospera resistance.

Abstract: The new variety ‘TH-1876’ ripens around early May in southern Georgia. The fruit of the new variety ‘TH-1876’ are large, firm and have good flavor and scar. The new variety ‘TH-1876’ is vigorous with an estimated chilling requirement of about 300 to 350 hours at or below approximately 7° C. The asexually reproduced variety is reliably propagated vegetatively.

Abstract: A new crapemyrtle plant has deep, uniform purple foliage and stems; a true pink flower color; an intermediate upright growth habit; and powdery mildew and Cercospera resistance.

Abstract: The new variety ‘TH-1125’ ripens around early May in south Georgia. The fruit of the new variety ‘TH-1125’ are large, firm and have good flavor. The new variety ‘TH-1125’ is vigorous with an estimated chilling requirement of about 250 to 300 hours at or below approximately 7° C. The asexually reproduced variety is reliably propagated vegetatively.

Abstract: A new cultivar of Ilex crenata plant named MAD-IC1, that is characterized by its broad columnar-fastigiate habit, its exceptional strong branches that do not splay, its coriaceous lustrous dark green pest-resistant foliage, and its propensity to produce shiny black fruits if a suitable pollinator is in proximity.

Abstract: A new and distinct muscadine grape plant, substantially as herein illustrated and described, characterized by dark red-colored berries; self-fertile flowers; berries that separate with a high percentage of dry stem scars; berries that are very large in size, and very productive vines with high total and usable yields.

Abstract: The new variety ‘TH-931’ is provided. The new and distinct variety ripens around late May in south Georgia and early June in middle Georgia. The fruit of the new variety ‘TH-931’ are very large and firm. The new variety ‘TH-931’ exhibits high yields with an estimated chilling requirement of about 400 to 500 hours at or below approximately 7° C. The asexually reproduced variety is reliably propagated vegetatively.

Abstract: The new variety ‘TH-1008’ is provided. The new and distinct variety flowers in early March in south Georgia, requiring frost protection for acceptable yields. The fruit of the new variety ‘TH-1008’ are ripen in early May in south Georgia and are very large, firm, and have good flavor. The new variety ‘TH-1008’ is compact with an estimated chilling requirement of about 200 to 300 hours at or below approximately 7° C. The asexually reproduced variety is reliably propagated vegetatively.